Search for Terms or Answers
TOGETHER-PsA by Merola et al may be a practice-changing obesity story. Adding tirzepatide to ixekizumab improved joint outcomes at 52 weeks. Treating inflammation alone may not be enough for some patients with PsA. @rheumnow #ACR2026 #ACRBest Abstract#2942
TOGETHER-PsA at 52 weeks: ACR50 was 43.7% with ixekizumab + tirzepatide vs 15.7% with ixekizumab alone in PsA with overweight/obesity. n=271; open-label RCT. Joint, functional and metabolic outcomes improved. #2942 @Rheumnow #ACR26 #ACRBest https://t.co/zMNyrbAR5m
Merola et al, TOGETHER-PsA: At 52 weeks, ACR50 was 43.7% with ixekizumab + tirzepatide vs 15.7% with ixekizumab alone. A 28-point difference! Is addressing obesity becoming essential to optimal PsA care? @rheumnow #ACR2026 #ACRBest Abstract#2942
Today the ACR began with the Great Debate, an intriguing set of Plenary presentations, a never-ending poster hall and a plethora of stimulation oral presentation sessions. Here are a few of my favorites from today:
Bimekizumab BEATS Risankizumab in PsA 24 week results by ACR50 from H2H BE-BOLD: - wk 4 19.9% vs. 7.2% - wk 16 49.1% vs. 38% - wk 24 54.9% vs. 43.8% More fungal infx in IL17 group as expected, mild-mod Practice-changing results for PsA @RheumNow #ACRbest #ACR26 Abst2804 https://t.co/3GxVLNs1td
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
